New Drug Combination Shows Promise for Peritoneal Mesothelioma
Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling a gaping void that exists today.
The immunotherapy drug combination of Tecentriq and Avastin, known generically as atezolizumab and bevacizumab, respectively, showed unusual efficacy in a recent study of 20 patients with this rare cancer.
Although some patients have previously found significant success and extended survival with the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combination, or HIPEC, those with unresectable disease ha...
Source: Asbestos and Mesothelioma News - July 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Oncotarget: RAS reversion in colorectal cancer patients treated with bevacizumab
(Impact Journals LLC) This Oncotarget finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news
Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient
(University of Texas M. D. Anderson Cancer Center) A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news
Edge Pharma Announces New Agreement with Cardinal Health ’s Acuity™ GPO
Edge Pharma, a 503B Outsourcing Facility, has entered into an agreement with Cardinal Health’s Acuity™ GPO to provide its member ophthalmology practices with Edge’s unit-dose MVASI™ (Bevacizumab-awwb)...(PRWeb July 14, 2021)Read the full story at https://www.prweb.com/releases/edge_pharma_announces_new_agreement_with_cardinal_healths_acuity_gpo/prweb18065310.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 14, 2021 Category: Pharmaceuticals Source Type: news
FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers
Hematology / Oncology Drug Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Drug Combination Disappoints in Advanced NSCLC Drug Combination Disappoints in Advanced NSCLC
Second-line bevacizumab plus osimertinib showed some PFS benefit over osimertinib alone in a subset of smokers/former smokers but overall showed no survival benefits in the ETOP BOOSTER trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Intravitreal bevacizumab cost saving for macular oedema in the UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2021 Category: Drugs & Pharmacology Source Type: news
Genentech defends breast cancer drug a decade after Avastin drama
"We all want to give patients hope — real hope, not false hope," said one opponent of allowing Genentech's Tecentriq to stay on the market. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 28, 2021 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Genentech defends breast cancer drug a decade after Avastin drama
"We all want to give patients hope — real hope, not false hope," said one opponent of allowing Genentech's Tecentriq to stay on the market. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 28, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news
New Combo Shows Benefit Even in Patients With High-Risk HCC New Combo Shows Benefit Even in Patients With High-Risk HCC
Updated data from the IMBRave150 trial show benefit for the combination of atezolizumab with bevacizumab even in patients with high-risk hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Biocon Biologics, Viatris Inc. get CHMP nod for Abevmy, a biosimilar to Avastin
Abevmy is abiosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen, it said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2021 Category: Pharmaceuticals Source Type: news
Atezolizumab + bevacizumab unlikely cost-effective first-line option in HCC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news
Anticancer drug may improve outcome for severe COVID-19 patients
Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020. On average, blood oxygen levels, body temperature and inflammatory markers significantly improved in patients treated with a single dose of bevacizumab in addition to standard care. (Source: World Pharma News)
Source: World Pharma News - February 8, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Anticancer drug may improve outcome for severe COVID-19 patients
(Karolinska Institutet) Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020. On average, blood oxygen levels, body temperature and inflammatory markers significantly improved in patients treated with a single dose of bevacizumab in addition to standard care. The research is published in Nature Communications. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2021 Category: Cancer & Oncology Source Type: news
Drug 'breakthrough' gives longest-ever survival in nonresectable liver cancer patients
(Spink Health) New follow-up data from a landmark study of liver cancer patients treated with a combination of an immunotherapy drug (atezolizumab) and a monoclonal antibody (bevacizumab) has shown the longest-ever survival time in a frontline phase 3 trial of systemic therapy in advanced hepatocellular carcinoma (HCC), demonstrating a 'major breakthrough' in the field. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2021 Category: Cancer & Oncology Source Type: news
